Cutera, Inc. (CUTR) At $43.40 Forms Top; Vbi Vaccines – Ordinary Shares (VBIV) Shorts Lowered By 1.67%

VBI Vaccines Inc. (NASDAQ:VBIV) Logo

Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) had a decrease of 1.67% in short interest. VBIV’s SI was 707,300 shares in June as released by FINRA. Its down 1.67% from 719,300 shares previously. With 121,800 avg volume, 6 days are for Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV)’s short sellers to cover VBIV’s short positions. The SI to Vbi Vaccines Inc – Ordinary Shares’s float is 1.84%. The stock decreased 6.38% or $0.24 during the last trading session, reaching $3.52. About 1.16 million shares traded or 463.80% up from the average. VBI Vaccines Inc. (NASDAQ:VBIV) has declined 26.86% since June 18, 2017 and is downtrending. It has underperformed by 39.43% the S&P500. Some Historical VBIV News: ; 12/03/2018 – VBI VACCINES – CO WILL CONTINUE TO HAVE “SIGNIFICANT” OPERATIONAL PRESENCE IN OTTAWA, CANADA; 22/05/2018 – Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress; 17/04/2018 – VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients; 17/04/2018 – VBI VACCINES: DSMB RECOMMENDS CONTINUATION OF VBI-1901 STUDY; 20/04/2018 – DJ VBI VACCINES INC COM, Inst Holders, 1Q 2018 (VBV); 19/04/2018 – VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac(R) Hepatitis B Vaccine; 17/04/2018 – VBI VACCINES INC – INDEPENDENT DATA AND SAFETY MONITORING BOARD UNANIMOUSLY RECOMMENDS CONTINUATION OF STUDY WITHOUT MODIFICATION; 01/05/2018 – VBI Vaccines 1Q Loss $12.3M; 19/04/2018 – VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine; 01/05/2018 – VBI Vaccines 1Q Loss/Shr 19c

Cutera, Inc. (CUTR) formed multiple top with $46.00 target or 6.00% above today’s $43.40 share price. Cutera, Inc. (CUTR) has $591.74 million valuation. The stock decreased 3.12% or $1.4 during the last trading session, reaching $43.4. About 281,512 shares traded or 8.97% up from the average. Cutera, Inc. (NASDAQ:CUTR) has risen 68.94% since June 18, 2017 and is uptrending. It has outperformed by 56.37% the S&P500. Some Historical CUTR News: ; 08/05/2018 – CUTERA INC CUTR.O SEES FY 2018 NON-GAAP SHR $1.03 TO $1.11; 08/05/2018 – Cutera Sees 2018 Adj EPS $1.03-Adj EPS $1.11; 08/05/2018 – Cutera 1Q Loss $2.03M; 08/05/2018 – CUTERA INC CUTR.O FY2018 SHR VIEW $0.95, REV VIEW $179.0 MLN — THOMSON REUTERS l/B/E/S; 08/05/2018 – Cutera Backs 2018 Rev $178M-$181M; 22/05/2018 – Cutera Presenting at UBS Conference Tomorrow; 16/03/2018 CUTERA INC FILES FOR NON-TIMELY 10-K – SEC FILING; 26/04/2018 – Cutera Presenting at UBS Conference May 23; 08/05/2018 – CUTERA INC CUTR.O SEES FY 2018 REVENUE $178 MLN TO $181 MLN; 14/05/2018 – Cutera Company Marketing Set By Stephens Inc. for May. 21-22

Among 5 analysts covering VBI Vaccines (NASDAQ:VBIV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VBI Vaccines had 7 analyst reports since July 26, 2016 according to SRatingsIntel. The stock of VBI Vaccines Inc. (NASDAQ:VBIV) earned “Buy” rating by Canaccord Genuity on Wednesday, November 1. The company was initiated on Monday, October 10 by Laidlaw. BMO Capital Markets initiated it with “Buy” rating and $11.0 target in Wednesday, November 15 report. The rating was initiated by Ladenburg Thalmann with “Buy” on Tuesday, July 26.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $226.04 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

More news for VBI Vaccines Inc. (NASDAQ:VBIV) were recently published by: Globenewswire.com, which released: “VBI Vaccines Announces Results of Annual General Meeting” on May 25, 2018. Nasdaq.com‘s article titled: “Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress” and published on May 22, 2018 is yet another important article.

Among 5 analysts covering Cutera (NASDAQ:CUTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cutera had 10 analyst reports since January 4, 2017 according to SRatingsIntel. As per Tuesday, August 8, the company rating was maintained by Roth Capital. Gabelli maintained the shares of CUTR in report on Tuesday, June 27 with “Buy” rating. Roth Capital maintained the shares of CUTR in report on Tuesday, September 12 with “Buy” rating. The rating was maintained by Maxim Group on Tuesday, August 8 with “Buy”. Maxim Group maintained the shares of CUTR in report on Wednesday, January 4 with “Buy” rating. The company was maintained on Thursday, July 13 by Maxim Group. Gabelli maintained Cutera, Inc. (NASDAQ:CUTR) on Wednesday, August 9 with “Buy” rating.

Analysts await Cutera, Inc. (NASDAQ:CUTR) to report earnings on August, 6. They expect $0.02 earnings per share, down 84.62% or $0.11 from last year’s $0.13 per share. CUTR’s profit will be $272,690 for 542.50 P/E if the $0.02 EPS becomes a reality. After $-0.15 actual earnings per share reported by Cutera, Inc. for the previous quarter, Wall Street now forecasts -113.33% EPS growth.

Since January 2, 2018, it had 4 insider purchases, and 4 insider sales for $831,331 activity. Barrett Gregory A bought $201,514 worth of stock. Shares for $99,537 were bought by Reinstein James A.. 2,000 Cutera, Inc. (NASDAQ:CUTR) shares with value of $71,200 were bought by FINNEY ELISHA W. $264,980 worth of Cutera, Inc. (NASDAQ:CUTR) was sold by Laber Larry on Tuesday, January 2. The insider GOLLNICK DAVID A sold $676,161.

Investors sentiment decreased to 0.8 in 2018 Q1. Its down 0.71, from 1.51 in 2017Q4. It is negative, as 21 investors sold Cutera, Inc. shares while 64 reduced holdings. 29 funds opened positions while 39 raised stakes. 11.89 million shares or 4.99% less from 12.51 million shares in 2017Q4 were reported. Gabelli Funds Ltd Liability Corporation reported 374,000 shares. Aqr Cap Management Limited Liability Com holds 0.01% or 132,246 shares. Spark Mgmt Ltd Company holds 0.28% of its portfolio in Cutera, Inc. (NASDAQ:CUTR) for 86,300 shares. Swiss Bancshares has 22,600 shares for 0% of their portfolio. Voya Inv Management Limited Liability Company reported 0% of its portfolio in Cutera, Inc. (NASDAQ:CUTR). 400,726 were accumulated by Partner Fund Mngmt Limited Partnership. Rice Hall James Assoc Limited Liability Co holds 0.06% or 30,269 shares. Moreover, Globeflex Capital L P has 0.17% invested in Cutera, Inc. (NASDAQ:CUTR) for 15,900 shares. North Star Management owns 400 shares for 0% of their portfolio. Acuta Limited Com accumulated 70,000 shares. Alps Advisors reported 9,020 shares. Cubist Systematic Strategies Ltd Liability Corp invested in 6,679 shares. Deutsche State Bank Ag accumulated 18,950 shares. Advsrs Asset Management holds 28,770 shares. Cortina Asset Lc holds 0.41% or 166,022 shares.

Cutera, Inc. (NASDAQ:CUTR) Institutional Positions Chart